Navigation Links
High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe, Finds Frost & Sullivan
Date:11/28/2012

LONDON, Nov. 28, 2012 /PRNewswire/ -- The rising incidence of diabetes in Europe has presented the diagnostics market with significant growth opportunities. Diabetes organizations expect the patient pool in Europe to reach 64.2 million by 2030. This will increase testing volumes and thereby promote the need for diagnostic products and accessories across labs and hospitals.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), European Diabetes Diagnostics Market, finds that the market earned revenues of over $3.97 billion in 2011 and estimates this to reach $5.93 billion in 2018.

The proven efficacy of point-of-care testing (POCT) HbA1c and glucose tests has encouraged their adoption. In most European countries, these tests are a part of routine screening programmes.

"Doctors and diabetes specialists recommend HbA1C tests once every three months for type 1 and type 2 diabetes patients," says Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. "Disease awareness programmes will further ensure regular monitoring of blood sugar levels."

However, low-cost suppliers are increasingly entering the market. This leads to stiff competition and intense pressure on established manufacturers to introduce innovative, automated and efficient monitors.

To achieve high profit margins, market participants must develop customised, result-oriented products. There is growing focus on self monitoring of blood glucose (SMBG), POCT HbA1C and glucose meters that can facilitate quicker measurements. Bundling these with other tests such as cholesterol monitoring is also essential.

"Non-invasive glucose meters with enhanced mobile connectivity and data management features in new systems are likely to dominate the market soon," notes Sashidhar. "Improved optical sensitivity and infra-red spectroscopy will improve work flow efficiencies."

Developing solutions with sufficient differentiation features is the key to staying competitive in this high-potential market.

If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

European Diabetes Diagnostics Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following areas: Antihypertensive Market in Select SADC Countries, Opportunity Analysis for Biosimilars in South Korea, European Alzheimer's Disease Medication Market, and Contract Research and Manufacturing Services Market in India. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. No Medical Degree Necessary: An Easy Guide to Understanding Your Probiotic Supplement Label
2. Berlin Packaging, Sanner USA Partner To Sell New Sanner 360 degree Desiccant Capsule In U.S.
3. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
4. iSALUS Healthcares chairman receives national honors from Samaritans Purse - an international organization providing spiritual and physical aid to victims of war, poverty, natural disaster and disease.
5. Research Published in European Journal of Pharmacology Shows that Star Scientifics Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimers Disease and in Blood
6. Exercise Rate Related to Improvements in Parkinsons Disease
7. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
8. Capital Digestive Care Leads the Way in the Fight to Unmask Reflux Disease During National GERD Awareness Week
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... Pass, OR (PRWEB) , ... April 29, 2016 , ... ... suggest dinner as the meal to miss. That was among the many new lifestyle ... Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and ...
(Date:4/29/2016)... ... , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 ... second place for Tampa’s Best Places to Work. They were ranked in the Big ... accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work hard ...
(Date:4/29/2016)... ... April 29, 2016 , ... Nike Softball Camp at the College of ... – 27th for girls aged 10-18. All facets of the game will be covered; ... V. Whited Complex, one of the finest softball facilities in the region. The outstanding ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst ... and coding services, and Deyta Analytics, recently announced the recipients of the fourth ... of quality as measured from the caregiver’s point of view. The official list ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions will be ... to 18th at the Broward County Convention Center. The event is a chance ... best practices in public facility management. Intellitec Solutions will highlight their customized accounting ...
Breaking Medicine News(10 mins):